Accurately classifying NSCLC as squamous or nonsquamous can be challenging^1-3. Routine histopathology is the current standard of lung tumor classification but has demonstrated only 60% to 70% concordance among different pathologists^1-3. Although considered by many as an improvement to current methods of diagnostics, the accuracy of lung cancer classification by IHC is also limited by the variable sensitivity and specificity of each marker. Technical inconsistencies and tumor heterogeneity can lead to inconsistent staining results. There is also a lack of standardization in interpretation of IHC results.


The shortcomings associated with current NSCLC classification methods point to the need for a highly accurate, objective, reproducible, and standardized classification tool in NSCLC diagnosis.

A single, conclusive test that differentiates squamous from nonsquamous NSCLC is finally available. miRview® squamous is a microRNA-based molecular diagnostic test that offers

• Accuracy
• Speed
• Simple interpretation
• Quantitative analysis
• Objective results
• Cutting-edge molecular biology

1. Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
2. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
3. Feinstein AR, Gelfman NA, Yesner R. Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis. 1970;101(5):671-684.
4. Hammar SP. Immunohistology of lung and pleural neoplasms. In: Dabbs D, ed. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2006:329-403.
5. Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37:542-546.
6. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443(2):122-132.
7. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19(3):417-428.
8. Au NH, Gown AM, Cheang M, et al. p63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004;12(3):240-247.
9. Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol. 2004;35(1):3-7.
10. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55(9):662-668.
11. Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003;34(6):597-604.